These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24016650)

  • 1. [Mechanisms of resistance to BCR-ABL kinase inhibitors].
    Diamond J; da Silva MG
    Acta Med Port; 2013; 26(4):402-8. PubMed ID: 24016650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance to BCR-ABL kinase inhibitors.
    Diamond JM; Melo JV
    Leuk Lymphoma; 2011 Feb; 52 Suppl 1():12-22. PubMed ID: 21299456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
    Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
    Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
    Lamontanara AJ; Gencer EB; Kuzyk O; Hantschel O
    Biochim Biophys Acta; 2013 Jul; 1834(7):1449-59. PubMed ID: 23277196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
    Melo JV; Chuah C
    Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to imatinib mesylate in chronic myeloid leukaemia.
    Melo JV; Chuah C
    Cancer Lett; 2007 May; 249(2):121-32. PubMed ID: 16949736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
    Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Part II: management of resistance to imatinib in chronic myeloid leukaemia.
    Apperley JF
    Lancet Oncol; 2007 Dec; 8(12):1116-1128. PubMed ID: 18054881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
    Bixby D; Talpaz M
    Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bypass mechanisms of resistance to tyrosine kinase inhibition in chronic myelogenous leukaemia.
    Marfe G; Di Stefano C
    Curr Drug Discov Technol; 2014 Jun; 11(2):145-53. PubMed ID: 24521199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
    Manley PW; Cowan-Jacob SW; Mestan J
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):3-13. PubMed ID: 16172030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
    Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
    Miura M; Takahashi N
    Rinsho Ketsueki; 2013 Oct; 54(10):1720-9. PubMed ID: 24064822
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
    Erba HP
    Am J Hematol; 2015 Mar; 90(3):242-9. PubMed ID: 25410137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.